Tregs, Tape, and Tresses

The RESOLVE-AD trial for moderate-to-severe atopic dermatitis introduces respegaldesleucin, an IL-2 receptor agonist designed to restore immune homeostasis by expanding regulatory T cells. While the drug shows a 61% mean reduction in EASI scores, concerns persist regarding its long-term safety and the potential for malignancy given the role of Tregs in immune evasion. In surgical practice, applying Steri-Strips parallel to incision edges provides a practical, low-cost solution for closing atrophic, fragile skin that otherwise tears under standard sutures. Furthermore, upadacitinib demonstrates significant efficacy in treating alopecia areata, with adolescent patients achieving SALT scores under 20 at rates near 80%. This JAK inhibitor shows superior performance compared to existing options, positioning it as a potential first-line therapy despite ongoing debates regarding the optimal JAK inhibitor selection for various dermatological conditions.